Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc.（XTNT）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · XTNT · 截至 2025年9月30日
股东结构概览
29
机构持有人数
$51.96M
机构持仓总市值
▼ $7.13M vs Q2
140.26M
总流通股
freeFloat 84.01%
80.06M
13F 申报持股数
▲ 101,444 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
XTNT 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
NANTAHALA CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 68.39M | 49.09% | 49.09% | $44.38B | Nov 14, 2025 | — held |
AWM INVESTMENT COMPANY, INC. biological products, (no diagnostic substances) | 6.59M | 4.73% | 4.73% | $4.28B | Nov 13, 2025 | ▼ 2.5K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.36M | 1.69% | 1.69% | $1.53B | Nov 7, 2025 | ▲ 104.2K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 713.9K | 51.25% | 51.25% | $463.26M | Nov 13, 2025 | ▲ 63.2K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 491.9K | 35.31% | 35.31% | $319.31M | Nov 12, 2025 | ▼ 61.7K |
CRESCENT GROVE ADVISORS, LLC biological products, (no diagnostic substances) | 412.0K | 29.58% | 29.58% | $267.36M | Nov 13, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 242.9K | 17.44% | 17.44% | $157.63M | Nov 14, 2025 | ▼ 19.6K |
BRIDGEWAY CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 164.1K | 11.78% | 11.78% | $106.48M | Nov 14, 2025 | — held |
PRIVATE ADVISOR GROUP, LLC biological products, (no diagnostic substances) | 123.0K | 8.83% | 8.83% | $79.81M | Nov 13, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 120.3K | 8.64% | 8.64% | $78.08M | Nov 12, 2025 | — held |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
7
增持
+202.9K 股4
新建仓
首次建仓6
减持
−86.1K 股4
清仓
完全退出净股数变化（前50家）
+116.8K
+202.9K / −86.1K
净新增持仓人
+1
新建 4 个 / 退出 4 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
XTNT 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
0
买入笔数
1
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Schallenberger Mark A. Chief Operating Officer | Feb 15, 2026 | Tax Withhold | 7,709 | $0.58 | $4.5K | 663.2K | Form 4 ↗ |
Neils Scott C CFO and Assistant Secretary | Jan 15, 2026 | Tax Withhold | 8,084 | $0.65 | $5.3K | 843.4K | Form 4 ↗ |
BAKEWELL JOHN K director | Nov 15, 2025 | Award | 158,228 | — | — | 914.1K | Form 4 ↗ |
Vizirgianakis Stavros G. director | Nov 15, 2025 | Award | 553,797 | — | — | 7.52M | Form 4 ↗ |
Beeson Jonn R. director | Nov 15, 2025 | Award | 158,228 | — | — | 517.6K | Form 4 ↗ |
BAKEWELL JOHN K director | Nov 15, 2025 | Award | 158,228 | — | — | 158.2K | Form 4 ↗ |
JAIN ABHINAV director | Nov 15, 2025 | Award | 158,228 | — | — | 158.2K | Form 4 ↗ |
Lipschultz Tyler director | Nov 15, 2025 | Award | 158,228 | — | — | 158.2K | Form 4 ↗ |
Browne Sean E President and CEO | Nov 15, 2025 | Award | 394,937 | — | — | 2.58M | Form 4 ↗ |
Browne Sean E President and CEO | Nov 15, 2025 | Award | 789,874 | — | — | 789.9K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Xtant Medical Holdings, Inc.（XTNT）主要由机构投资者持有，机构持股比例约为 57.1%。公司内部人员持股约 15.99%，散户及公众持股约占剩余的 26.93%。
Xtant Medical Holdings, Inc. 最大机构股东为 NANTAHALA CAPITAL MANAGEMENT, LLC，截至 September 30, 2025 持有约 68.39 million 股，占总流通股的 49.09%。
目前共有 29 家机构持有 XTNT 股票，合计持仓市值约 $51,958,021，数据来源为最新 SEC 13F 申报。
常见问题
XTNT ownershipXtant Medical Holdings, Inc.（XTNT）主要由机构投资者持有，机构持股约 57.1%。最大股东为 NANTAHALA CAPITAL MANAGEMENT, LLC，持股比例 49.09%。内部人员持股约 15.99%。数据来源 SEC Form 13F，截至 September 30, 2025。